Market access

In-Depth Analysis: Market Access –

For life science companies around the world, enabling faster access to innovative drugs and therapies is a complex challenge. As the contributors to this issue discuss, changes in technologies and processes across the industry are disrupting traditional market access solutions and creating opportunities for companies to explore new avenues of innovation.

Read on to find out how diverse perspectives are reshaping value, the importance of making patient centricity a reality, and more.

Bridging the Digital Expectation Gap in the Pharmaceutical Industry
To compete in the digital world, the pharmaceutical industry must catch up with other industries by creating seamless online experiences, says Takeda’s Jan Deman

Combined Pricing: Access to the Future of Oncology Treatment
Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but around the world, says Sanofi’s Fleur Chandler

Rethinking Value: Why Diverse Viewpoints Matter
Defining and demonstrating value is a dynamic process, as stakeholders are likely to have different perceptions of “good”, says AXON’s Shanida Nataraja

How to make patient orientation a reality?
Giving patients a seat at the table is critical as real-time patient data grows in importance. Evidation Co-Founder Mikki Nasche on How to Turn Patient-Centered Talk into Action

Leverage KOL insights to succeed in a data-driven world
New engagement strategies are needed to effectively interact with KOLs as companies seek to explore more virtual spaces, says Christina Hoffman of Medscape Medical Affairs

Is it time to rethink electronic prescribing in the United States?
As major industry players come under scrutiny from trade regulators, a new wave of e-prescribing companies has begun to emerge in the United States.

The importance of neonatal screening for SMA
Early identification of spinal muscular atrophy is essential for an infant’s health, but many countries do not include AMS in their national NBS panels, as Mike Fraser of Novartis explains.

Read Deep Dive: Market Access in full

The digital pharmaphorum magazine Deep Dive provides unbiased, problem-driven viewpoints, analysis, high-profile interviews and unique research for pharmaceutical companies, biotech companies and the broader healthcare industry. Subscribe to upcoming issues of Deep Dive.